Fibroblast Cell Lines Homozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Screening of Small Molecules for Gaucher Disease Treatment

Description:
This technology includes two human fibroblast cell lines be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. Glucocerebrosidase (GBA1 or GCase or beta-glucosidase) is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneous disorder, caused by inherited genetic mutations in GBA1. Inventors have collected fibroblasts from various patients, including those with homozygous mutation N370S. This is the most common mutation found in Gaucher patients and is found in the non-neuronopathic form of the disease.
Patent Information:
For Information, Contact:
Eggerton Campbell
Licensing And Patenting Manager
NIH Technology Transfer
301-402-1648
eggerton.campbell@nih.gov
Inventors:
Barbara Stubblefield
Ellen Sidransky
Keywords:
Cell
Fibroblast
GBA1
GLUCOCEREBROSIDASE
HOMOZYGOUS
Lines
Listed LPM Vepa as of 4/15/2015
MUTATION
N370S
Post LPM Assignment Set 20150420
Pre LPM working set 20150418
VPXXXX
WIXXXX
WKXXXX
XHXXXX
© 2024. All Rights Reserved. Powered by Inteum